Welcome to our dedicated page for VIE news (Ticker: VIE), a resource for investors and traders seeking the latest updates and insights on VIE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VIE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VIE's position in the market.
Viela Bio (Nasdaq: VIE) announced its fourth quarter and full-year 2020 financial results, highlighting significant progress in its pipeline despite pandemic challenges. The company reported a net product revenue of $9.4 million for Q4 2020, and $11.7 million for the full year. However, net losses increased to $33.4 million for Q4 and $150.7 million for the year. Viela received FDA approval for UPLIZNA®, leading to positive sales uptake and ongoing clinical trials. Additionally, a definitive agreement for Horizon Therapeutics to acquire Viela at $53.00 per share was announced.
Viela Bio (Nasdaq: VIE) announced updated results from the N-MOmentum trial for UPLIZNA (inebilizumab-cdon), focusing on safety and efficacy in treating neuromyelitis optica spectrum disorder (NMOSD). Key findings show sustained attack reduction in over four years, with 96.3% of patients attack-free at six months. Importantly, no new safety signals emerged with prolonged treatment. The company presented interim data at the ACTRIMS 2021 Forum, reinforcing UPLIZNA's potential as a long-term treatment option for NMOSD patients.
Viela Bio (Nasdaq: VIE) announced it will release its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. The company is currently involved in a merger with Horizon Therapeutics, announced on February 1, 2021. As a result, Viela will not hold a conference call for the earnings report. Relevant materials will be available on the company's Investor Relations page. Viela Bio focuses on developing treatments for autoimmune and severe inflammatory diseases.
Horizon Therapeutics (HZNP) has announced a definitive agreement to acquire Viela Bio (VIE) for $53.00 per share, totaling approximately $3.05 billion. The acquisition, aimed at expanding Horizon's pipeline and enhancing long-term growth, is expected to close by the end of Q1 2021. Horizon plans to finance the acquisition through $1.3 billion in external debt and cash reserves. The deal adds Viela's FDA-approved UPLIZNA and its mid-stage biologics pipeline, significantly strengthening Horizon's position in the autoimmune and severe inflammatory disease market.
Viela Bio (Nasdaq: VIE) reported Q3 2020 results, generating $2.3 million in net product sales from UPLIZNA®, a significant increase from no sales in Q3 2019. The net loss narrowed to $37.6 million from $48.4 million year-over-year. As of September 30, 2020, the company holds $387.5 million in cash, with no debt. Viela continues to expand UPLIZNA's indications and has ongoing trials for other investigational drugs, including VIB4920 and VIB7734, while navigating challenges due to the COVID-19 pandemic.
Viela Bio has announced final data from its Phase 1b trial of VIB7734 for cutaneous lupus erythematosus (CLE). This monoclonal antibody significantly depleted plasmacytoid dendritic cells (pDCs) in patients, resulting in notable reductions in skin lesions, as measured by the CLASI-A score. The trial demonstrated a median decline in interferon levels and an acceptable safety profile. With 75% of patients in the 150 mg group achieving a ≥50% improvement in CLASI-A, Viela aims to initiate a Phase 2 trial for systemic lupus erythematosus (SLE) in early 2021.
Viela Bio (Nasdaq: VIE) will host a webcast and conference call on November 10, 2020, at 5:00 p.m. EST to discuss its third-quarter 2020 financial results and program highlights. The event will be accessible via the company's Events & Presentations page, with participation available through specified phone numbers.
Viela Bio (Nasdaq: VIE) announced the acceptance of four abstracts for the 8th Joint Congress of ACTRIMS and ECTRIMS, taking place virtually from September 11-13, 2020. This includes a late-breaker presentation on pharmacodynamic modeling of inebilizumab for neuromyelitis optica spectrum disorders scheduled for September 26, 2020. Presentations will cover critical findings from the N-MOmentum trial, highlighting insights into patient responses and MRI activity in neuromyelitis optica.
Viela Bio (Nasdaq:VIE) reported its Q2 2020 financial results, highlighting the FDA approval of UPLIZNA™ for neuromyelitis optica spectrum disorder. The company raised approximately $169 million through a public offering, extending its cash runway into 2023. Despite a net loss of $38.9 million, Viela shows potential with ongoing trials for inebilizumab in myasthenia gravis and IgG4-related disease. Positive interim data from the Phase 1b trial of VIB7734 supports its advancement into a Phase 2 trial focused on systemic lupus erythematosus.
Viela Bio (Nasdaq: VIE) will host a webcast and conference call on August 12, 2020, at 5:00 p.m. ET to discuss its second quarter 2020 financial results and program highlights. The call will be available via their Events & Presentations webpage, and participants can join by calling (877) 783-8848 (domestic) or (631) 350-0960 (international) with conference ID #: 4945969. The archived webcast will be accessible shortly after the event.
